Erythropoietin and a hypoxia‐inducible factor prolyl hydroxylase inhibitor (HIF‐PHDi) lowers FGF23 in a model of chronic kidney disease (CKD)
Abstract Iron‐deficiency anemia is a potent stimulator of the phosphaturic hormone Fibroblast growth factor‐23 (FGF23). Anemia, elevated FGF23, and elevated serum phosphate are significant mortality risk factors for patients with chronic kidney disease (CKD). However, the contribution of anemia to o...
Main Authors: | Megan L. Noonan, Erica L. Clinkenbeard, Pu Ni, Elizabeth A. Swallow, Samantha P. Tippen, Rafiou Agoro, Matthew R. Allen, Kenneth E. White |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-06-01
|
Series: | Physiological Reports |
Subjects: | |
Online Access: | https://doi.org/10.14814/phy2.14434 |
Similar Items
-
Hypoxia Pathway Proteins are Master Regulators of Erythropoiesis
by: Deepika Watts, et al.
Published: (2020-10-01) -
Plasmatic Klotho and FGF23 Levels as Biomarkers of CKD-Associated Cardiac Disease in Type 2 Diabetic Patients
by: Ana Paula Silva, et al.
Published: (2019-03-01) -
Hypoxia, HIF, and Associated Signaling Networks in Chronic Kidney Disease
by: Jing Liu, et al.
Published: (2017-04-01) -
Osteocytic FGF23 and Its Kidney Function
by: Rafiou Agoro, et al.
Published: (2020-08-01) -
HIF-α Prolyl Hydroxylase Inhibitors and Their Implications for Biomedicine: A Comprehensive Review
by: Kiichi Hirota
Published: (2021-04-01)